KMDA
VENTE TOTALE: 177 173 titres (~1 463 733,74 $ US)
- Insiders
- Tsur David
- Total bought
- —
- Total sold
- $1,463,734
- Last activity
- 2026-09-09
- Last synced
-
2026-09-12 10:11:06
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-11
KMDA exhibits genuinely strong financial health — solid liquidity (90), improving fundamentals (85), and a clear profitability turnaround — but the event-driven signal is a significant drag, with a catalyst score of…
The first sentence of the analysis written for KMDA on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 42.3% | 43.5% | 38.9% | 36.1% | 29.3% | |
| Ebit Margin | 13.5% | 8.7% | 6.8% | -1.0% | -1.5% | |
| Ebitda Margin | 21.7% | 17.3% | 14.9% | 8.4% | 3.9% | |
| Operating Profit Margin | 14.5% | 12.5% | 7.1% | 3.5% | -0.7% | |
| Pretax Profit Margin | 13.0% | 8.3% | 5.9% | -1.7% | -1.8% | |
| Continuous Operations Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Net Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Bottom Line Profit Margin | 11.2% | 9.0% | 5.8% | -1.8% | -2.2% | |
| Current Ratio | 4.074 | 3.733 | 3.427 | 1.836 | 2.406 | |
| Quick Ratio | 2.282 | 2.137 | 1.643 | 0.878 | 1.077 | |
| Solvency Ratio | 0.320 | 0.251 | 0.178 | 0.067 | 0.024 | |
| Cash Ratio | 1.592 | 1.588 | 1.122 | 0.453 | 0.344 | |
| Price To Earnings Ratio | 18.579 | 24.360 | 36.000 | -77.413 | -132.129 | |
| Price To Earnings Growth Ratio | 0.357 | 0.518 | -0.084 | -19.276 | 1.181 | |
| Forward Price To Earnings Growth Ratio | 0.357 | 0.518 | -0.084 | -19.276 | 1.181 | |
| Price To Earnings Diluted Ratio | 19.081 | 24.360 | 40.800 | -77.413 | -132.129 | |
| Price To Earnings Diluted Growth Ratio | 0.398 | 0.365 | -0.105 | -19.276 | 1.178 | |
| Price To Book Ratio | 1.512 | 1.349 | 1.225 | 1.021 | 1.666 | |
| Price To Sales Ratio | 2.255 | 2.175 | 2.097 | 1.389 | 2.842 | |
| Price To Free Cash Flow Ratio | 24.033 | 9.500 | -194.686 | 7.246 | -22.583 | |
| Price To Operating Cash Flow Ratio | 14.750 | 7.356 | 69.257 | 6.287 | -32.135 | |
| Debt To Assets Ratio | 0.031 | 0.030 | 0.025 | 0.064 | 0.076 | |
| Debt To Equity Ratio | 0.043 | 0.043 | 0.036 | 0.117 | 0.138 | |
| Debt To Capital Ratio | 0.041 | 0.041 | 0.035 | 0.105 | 0.121 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.069 | 0.090 | |
| Financial Leverage Ratio | 1.407 | 1.435 | 1.454 | 1.831 | 1.802 | |
| Working Capital Turnover Ratio | 1.286 | 1.261 | 1.552 | 1.857 | 0.905 | |
| Operating Cash Flow Ratio | 0.582 | 0.964 | 0.087 | 0.378 | -0.170 | |
| Operating Cash Flow Sales Ratio | 0.153 | 0.296 | 0.030 | 0.221 | -0.088 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.614 | 0.774 | -0.356 | 0.868 | 1.423 | |
| Debt Service Coverage Ratio | 12.052 | 43.833 | 16.219 | 2.006 | 1.257 | |
| Interest Coverage Ratio | 30.362 | 30.380 | 7.753 | 4.958 | -2.459 | |
| Short Term Operating Cash Flow Coverage Ratio | 13.006 | 0.000 | 0.000 | 6.432 | -3.484 | |
| Operating Cash Flow Coverage Ratio | 2.386 | 4.302 | 0.489 | 1.388 | -0.376 | |
| Capital Expenditure Coverage Ratio | 2.589 | 4.431 | 0.738 | 7.554 | -2.364 | |
| Dividend Paid And Capex Coverage Ratio | 1.192 | 4.431 | 0.738 | 7.554 | -2.364 | |
| Dividend Payout Ratio | 0.618 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.741 | 10.169 | 11.890 | 15.361 | 74.960 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 42.3% | ▼-1.1% | ▲4.3% |
| Ebit Margin | 13.5% | ▲4.8% | ▲8.2% |
| Ebitda Margin | 21.8% | ▲4.5% | ▲8.5% |
| Operating Profit Margin | 14.5% | ▲2.1% | ▲7.2% |
| Pretax Profit Margin | 13.0% | ▲4.7% | ▲8.3% |
| Continuous Operations Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Net Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Bottom Line Profit Margin | 11.2% | ▲2.2% | ▲6.8% |
| Current Ratio | 4.074 | ▲0.341 | ▲0.979 |
| Quick Ratio | 2.282 | ▲0.145 | ▲0.678 |
| Solvency Ratio | 0.320 | ▲0.070 | ▲0.152 |
| Cash Ratio | 1.592 | ▲0.004 | ▲0.573 |
| Price To Earnings Ratio | 18.579 | ▼-5.781 | ▲44.700 |
| Price To Earnings Growth Ratio | 0.357 | ▼-0.160 | ▲3.818 |
| Forward Price To Earnings Growth Ratio | 0.357 | ▼-0.160 | ▲3.818 |
| Price To Earnings Diluted Ratio | 19.081 | ▼-5.279 | ▲44.141 |
| Price To Earnings Diluted Growth Ratio | 0.398 | ▲0.032 | ▲3.885 |
| Price To Book Ratio | 1.512 | ▲0.163 | ▲0.158 |
| Price To Sales Ratio | 2.255 | ▲0.080 | ▲0.103 |
| Price To Free Cash Flow Ratio | 24.033 | ▲14.534 | ▲59.331 |
| Price To Operating Cash Flow Ratio | 14.750 | ▲7.394 | ▲1.647 |
| Debt To Assets Ratio | 0.030 | ▲0.001 | ▼-0.015 |
| Debt To Equity Ratio | 0.043 | ▲0.000 | ▼-0.032 |
| Debt To Capital Ratio | 0.041 | ▲0.000 | ▼-0.027 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.032 |
| Financial Leverage Ratio | 1.407 | ▼-0.027 | ▼-0.179 |
| Working Capital Turnover Ratio | 1.286 | ▲0.025 | ▼-0.086 |
| Operating Cash Flow Ratio | 0.582 | ▼-0.382 | ▲0.214 |
| Operating Cash Flow Sales Ratio | 0.153 | ▼-0.143 | ▲0.031 |
| Free Cash Flow Operating Cash Flow Ratio | 0.614 | ▼-0.161 | ▼-0.051 |
| Debt Service Coverage Ratio | 12.052 | ▼-31.782 | ▼-3.022 |
| Interest Coverage Ratio | 30.362 | ▼-0.018 | ▲16.163 |
| Short Term Operating Cash Flow Coverage Ratio | 13.006 | ▲13.006 | ▲9.816 |
| Operating Cash Flow Coverage Ratio | 2.386 | ▼-1.916 | ▲0.748 |
| Capital Expenditure Coverage Ratio | 2.589 | ▼-1.843 | ▼-0.001 |
| Dividend Paid And Capex Coverage Ratio | 1.192 | ▼-3.239 | ▼-1.118 |
| Dividend Payout Ratio | 0.618 | ▲0.618 | ▲0.494 |
| Enterprise Value Multiple | 8.741 | ▼-1.429 | ▼-15.483 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $407.0M | $350.1M | $298.8M | $179.7M | $294.6M | |
| Enterprise value | $343.1M | $282.7M | $252.0M | $166.1M | $300.4M | |
| EV / Sales | 1.90x | 1.76x | 1.77x | 1.28x | 2.90x | |
| EV / Op. cash flow | 12.43x | 5.94x | 58.41x | 5.81x | -32.76x | |
| EV / Free cash flow | 20.26x | 7.67x | -164.19x | 6.70x | -23.02x | |
| EV / EBITDA | 8.74x | 10.17x | 11.89x | 15.36x | 74.96x | |
| Net debt / EBITDA | -1.63x | -2.42x | -2.21x | -1.26x | 1.44x | |
| Current ratio | 4.07x | 3.73x | 3.43x | 1.84x | 2.41x | |
| Income quality | 1.26x | 3.29x | 0.52x | -12.32x | 3.96x | |
| Graham number | $6 | $5 | $4 | — | — | |
| Graham net-net | $1 | $0 | $0 | -$1 | -$1 | |
| Tax burden | 86.1% | 108.5% | 98.3% | 102.7% | 118.3% | |
| Interest burden | 96.4% | 95.3% | 86.7% | 168.0% | 117.7% | |
| Working capital | $145.7M | $135.0M | $120.4M | $63.3M | $76.0M | |
| Invested capital | $322.4M | $313.0M | $296.3M | $239.0M | $259.0M | |
| Return on assets | 5.3% | 3.9% | 2.3% | -0.7% | -0.7% | |
| Operating ROA | 7.0% | 5.5% | 3.0% | 1.4% | -0.3% | |
| Return on tangible assets | 8.0% | 6.0% | 3.9% | -1.3% | -1.4% | |
| Return on equity | 7.5% | 5.6% | 3.4% | -1.3% | -1.3% | |
| Return on invested capital | 6.8% | 6.2% | 3.2% | 1.8% | -0.3% | |
| Return on capital employed | 7.9% | 6.2% | 3.3% | 1.8% | -0.3% | |
| Earnings yield | 5.0% | 4.1% | 2.8% | -1.3% | -0.8% | |
| Free cash flow yield | 4.2% | 10.5% | -0.5% | 13.8% | -4.4% | |
| Capex / Op. cash flow | 38.6% | 22.6% | 135.6% | 13.2% | -42.3% | |
| Capex / Depreciation | 66.0% | 77.8% | 46.0% | 31.1% | 66.5% | |
| Capex / Sales | 5.9% | 6.7% | 4.1% | 2.9% | 3.7% | |
| SG&A / Sales | 18.8% | 19.2% | 19.3% | 19.4% | 16.9% | |
| R&D / Sales | 7.2% | 9.4% | 9.8% | 10.2% | 11.0% | |
| Stock comp / Sales | 0.0% | 0.5% | 0.9% | 0.9% | 0.0% | |
| Intangibles / Total assets | 33.4% | 35.5% | 39.4% | 45.6% | 48.2% | |
| Days sales outstanding | 59d | 53d | 55d | 80d | 125d | |
| Days payables outstanding | 82d | 111d | 104d | 145d | 125d | |
| Operating cycle | 357d | 369d | 426d | 400d | 483d | |
| Cash conversion cycle | 275d | 258d | 322d | 255d | 358d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+16.2%EV / Sales ▲+8.2%EV / EBITDA ▼-14.0%EV / Op. cash flow ▲+6.493Earnings yield ▲+0.008Graham number ▲+1.012
Profitability
Return on equity ▲+0.019Return on assets ▲+0.014Return on invested capital ▲+0.006Return on capital employed ▲+0.017Operating ROA ▲+0.015Income quality ▼-2.029Tax burden ▼-0.224
Efficiency
Days sales outstanding ▲+6.144Days payables outstanding ▼-29.716Operating cycle ▼-12.020Cash conversion cycle ▲+17.696Capex / Sales ▼-0.008R&D / Sales ▼-0.022
Balance-sheet strength
Current ratio ▲+0.341Net debt / EBITDA ▲+0.795Working capital ▲+10753243.000Invested capital ▲+9430919.000Intangibles / Total assets ▼-0.021
Change over 5 years
Valuation
Market cap ▲+38.1%EV / Sales ▼-34.4%EV / EBITDA ▼-88.3%EV / Op. cash flow ▲+45.197Earnings yield ▲+0.057
Profitability
Return on equity ▲+0.088Return on assets ▲+0.060Return on invested capital ▲+0.070Return on capital employed ▲+0.082Operating ROA ▲+0.072Income quality ▼-2.693Tax burden ▼-0.322
Efficiency
Days sales outstanding ▼-66.491Days payables outstanding ▼-43.437Operating cycle ▼-126.076Cash conversion cycle ▼-82.639Capex / Sales ▲+0.022R&D / Sales ▼-0.038
Balance-sheet strength
Current ratio ▲+1.668Net debt / EBITDA ▼-3.067Working capital ▲+69724243.000Invested capital ▲+63444919.000Intangibles / Total assets ▼-0.148
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-10 Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.
- 2026-09-03 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company''s ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).
- 2026-08-17 Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Dividend to be Paid Consistent with the Company''s Cash Dividend Policy Dividend to be Paid Consistent with the Company''s Cash Dividend Policy
- 2026-08-14 Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
- 2026-08-14 KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-08-14 Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-12 Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
- 2026-08-12 Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-12 Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.
- 2026-08-12 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada''s History; Affirms 2026 Annual Guidance REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and six months ended June 30, 2026.